

Title: Interim President & CEO, CIRM

Duration: Until filled by permanent hire

Percent Effort: [50%-100%]

Annualized Salary Based on FTE: [+439k-650k]

Responsibilities:

The Interim Chief Executive Officer responsible to the Board for effectively leading the CIRM team during the search for a permanent Chief Executive. The Interim CEO's primary responsibility will be to create stability, provide strategic leadership to the team, and implement key short-term operational plans to address immediate organizational needs. The Interim CEO will:

- Review internal processes, procedures, morale and identify key areas for short- and longer-term areas of opportunity.
- Communicate regularly with Board Leadership to ensure Presidential Search process is situationally aware while it conducts its search.
- Work with Board Leadership to prioritize time-sensitive decisions/direction that need board attention.
- Work with the team to prepare the FY24/25 research and administrative budgets.
- Identify areas from the just-completed performance audit that may be addressed in the short term (consistent with the expectations above) and those areas which should be reserved for leadership from the permanent CEO.
- Oversee the Leadership Team meetings and direct workflow.
- Participate in all institute Working Group meetings.
- Prepare the Annual Report.
- Ensure Institute policies are current and recommend updates where appropriate.

It will not be necessary for the interim leader to:

- Change out members of the Leadership Team without consulting the Chair and Vice-Chair
- Conduct an institute-wide reorganization.
- Dramatically shift relationships with external stakeholders.
- Remake of anything with symbolic significance (the mission, a web site overhaul, a new logo, etc.).

To Be Clarified:

- Whether and how Interim CEO will support ongoing board committee and working group efforts. Key areas in question:
 - Neuro Task Force
 - Science Subcommittee work on Leverage (Prioritization)
 - Rare Disease Strategy – Workshop action plan for 2024
 - Patient Support Program – ICOC selection of awardee
- Whether the Interim CEO should continue to lead development of internal projects at various stages of progress:
 - New CLIN funding to conduct Consortia Trials (Basket trials, Umbrella trials, & platform trials) to be applied to neurological diseases such as Gliomas and/or Parkinson’s disease.
 - Per a landmark FDA publication, New England J Med 377, July 6, 2017, consortia trials are also known as master protocols are often classified into “basket trials”, “umbrella trials”, and “platform trials”.
 - Basket trials refer to designs in which a targeted therapy is evaluated on multiple diseases that have common molecular alternations.
 - Umbrella trials, evaluate multiple targeted therapies for a single disease that is stratified into subgroups by molecular alternation.
 - Platform trials are trials that evaluate several interventions against a common control group and can be perpetual as was done with ISPY-2 for breast cancer and more recently with ALS and COVID.
 - Data Coordinating and Management Center (DCMC): Central hub for managing and coordinating data-related activities from CIRM-funded research awards.